Trial results

Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth

NCT06934655 on ClinicalTrials.gov · last registry update 2026-09-02

A small phase 3 — 150 participants, against a typical 424. Due to report 1 November 2030. Primary outcome, as filed: Percent Body Mass Index. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

RECRUITING

Phase

P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Children's Hospital Los Angeles

Sponsor type

Other

Enrollment

150

Started

2026-09-01

Primary completion

2030-11-01 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Percent Body Mass Index

Conditions studied

Pediatric Obesity · Metabolic and Bariatric Surgery · Semaglutide

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.